The present invention relates to compounds of formula (I), and pharmaceutically acceptable salts thereof. The present invention further relates to the compounds of formula (I) for use as a medicament and to a pharmaceutical composition comprising said compounds. The compounds provided herein can act as prodrugs that, upon administration, release N,N-dimethyltryptamine (DMT) or a derivative thereof and exhibit improved pharmacokinetic properties, which renders these compounds highly advantageous for use in therapy.
2a2a-receptor, these prodrugs are particularly advantageous for use in therapy, e.g., in the treatment of depression, posttraumatic stress disorder (PTSD), Alzheimer's disease or dementia.
C07C 251/18 - Compounds containing nitrogen atoms doubly- bound to a carbon skeleton containing imino groups having carbon atoms of imino groups bound to carbon atoms of rings other than six-membered aromatic rings
A61P 1/08 - Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigoAntiemetics
A61P 25/00 - Drugs for disorders of the nervous system
C07D 201/00 - Preparation, separation, purification, or stabilisation of unsubstituted lactams
A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
C07C 255/24 - Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms containing cyano groups and singly-bound nitrogen atoms, not being further bound to other hetero atoms, bound to the same saturated acyclic carbon skeleton
C07C 271/12 - Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals
C07C 271/16 - Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of hydrocarbon radicals substituted by singly-bound oxygen atoms
C07D 411/12 - Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
The present invention provides a novel group of active peptide compounds based on the psychoactive safrylamine compounds MDMA, MDA, MMDA-2, and MDAI. Thereby, the invention provides for improved pharmacokinetic properties during uptake of the safrylamines, as well as reduced side effects resulting from the metabolites thus formed. Due to the affinity of the novel safrylamine derivatives for the 5-HT2a-receptor, the invention can find use in numerous forms of therapy, such as against depression or posttraumatic stress disorder (PTSD).
C07D 405/12 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
C07D 317/58 - Radicals substituted by nitrogen atoms
C07D 317/70 - Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with ring systems containing two or more relevant rings
A61P 25/00 - Drugs for disorders of the nervous system
4.
IMPROVED METHOD FOR THE PRODUCTION OF LYSERGIC ACID DIETHYLAMIDE (LSD) AND NOVEL DERIVATIVES THEREOF
The present invention provides an improved method for the production of lysergic acid diethylamide (LSD) for GMP purposes. Furthermore, the present invention provides novel LSD derivatives of formula I as well as their synthesis and purification. Due to the affinity of the presented substances for the 5-HT2A receptor, the invention may find application in numerous forms of therapy, such as against depression or drug addiction.
C07D 457/08 - Lysergic acid amides in which the amide nitrogen is a member of a heterocyclic ring
C07D 519/00 - Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups or
patents
